NCT05549297 2026-02-25
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Immunocore Ltd
Phase 3 Recruiting
Clinical Trials
4 trialsNCT02535078 2024-07-24
Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma
Immunocore Ltd
Phase 1/2 Withdrawn
NCT02570308 2023-03-21
A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma
Immunocore Ltd
Phase 1/2 Completed
NCT04960891 2022-01-21
Non Applicable
Immunocore Ltd
Available